Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 391 to 405 of 878 results for score

  1. Transcervical ultrasound-guided radiofrequency ablation for symptomatic uterine fibroids (HTG572)

    Evidence-based recommendations on transcervical ultrasound-guided radiofrequency ablation for symptomatic uterine fibroids in adults. This involves inserting a device through the cervix into the womb to destroy the fibroid using radiofrequency energy.

  2. Coil embolisation of unruptured intracranial aneurysms (HTG63)

    Evidence-based recommendations on coil embolisation of unruptured intracranial aneurysms. This involves placing coils inside the aneurysm using a thin tube to make the blood clot so it is less likely to burst.

  3. Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA445)

    Evidence-based recommendations on certolizumab pegol (Cimzia) and secukinumab (Cosentyx) for treating active psoriatic arthritis in adults.

  4. Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments (TA930)

    Evidence-based recommendations on lutetium-177 vipivotide tetraxetan (Pluvicto) for treating prostate-specific membrane antigen-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments in adults.

  5. Focal therapy using high-intensity focused ultrasound for localised prostate cancer (HTG667)

    Evidence-based recommendations on focal therapy using high-intensity focused ultrasound for localised prostate cancer. This involves using high-intensity focused ultrasound to heat up and destroy only the areas of the prostate with cancer (focal therapy). The aim is to destroy the cancer while reducing damage to healthy prostate tissue.

  6. The MIST Therapy system for the promotion of wound healing (HTG267)

    Evidence-based recommendations on the MIST Therapy system for the promotion of wound healing.

  7. Remsima (infliximab biosimilar) for subcutaneous injection for managing rheumatoid arthritis (ES29)

    Summary of the evidence on remsima (infliximab biosimilar) for subcutaneous injection for managing rheumatoid arthritis

  8. FreeO2 automatic oxygen titration for chronic obstructive pulmonary disease and respiratory distress syndrome (MIB281)

    NICE has developed a medtech innovation briefing (MIB) on FreeO2 automatic oxygen titration for chronic obstructive pulmonary disease and respiratory distress syndrome .

  9. Ponesimod for treating relapsing–remitting multiple sclerosis (TA767)

    Evidence-based recommendations on ponesimod (Ponvory) for treating relapsing–remitting multiple sclerosis in adults.

  10. Vortioxetine for treating major depressive episodes (TA367)

    Evidence-based recommendations on vortioxetine (Brintellix) for treating major depressive episodes in adults.

  11. Lung cancer: diagnosis and management (NG122)

    This guideline covers diagnosing and managing non-small-cell and small-cell lung cancer. It aims to improve outcomes for people by ensuring that they get the most effective tests and treatments, and that they have access to suitable palliative care and follow-up.

  12. Digital therapy for chronic tic disorders and Tourette syndrome: early value assessment (HTG748)

    Early value assessment (EVA) guidance on digital therapy for chronic tic disorders and Tourette syndrome.

  13. Transcranial magnetic stimulation for treating and preventing migraine (HTG330)

    Evidence-based recommendations on transcranial magnetic stimulation for treating and preventing migraine. This involves placing a handheld device on the scalp to deliver magnetic pulses to the head.

  14. Balloon cryoablation for Barrett's oesophagus (HTG767)

    Evidence-based recommendations on balloon cryoablation for Barrett's oesophagus. This involves freezing and destroying the abnormal cells using a balloon inflated with very cold gas.

  15. Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroids (TA832)

    Evidence-based recommendations on relugolix–estradiol–norethisterone acetate (Ryeqo) for treating moderate to severe symptoms of uterine fibroids in adults of reproductive age.